Renewable Petroleum Company LS9 Announces Distinguished Hire

LS9

Renewable Petroleum Company LS9 Announces Distinguished Hire

June 18, 2007

SAN CARLOS, Calif., June 18 /PRNewswire/ -- LS9, the Renewable Petroleum Company (TM), today announced that it has named Dr. Fernando Valle as its Senior Director of Metabolic Engineering, a key position in its effort to commercially deliver a clean, renewable petroleum substitute. LS9 will offer a broad portfolio of DesignerBiofuels (TM) products that are lab-engineered for various commercial end-uses, including custom, fit-for-purpose gasoline, diesel, and jet fuel formulations.

Dr. Fernando Valle has spent much of his 25-year career advancing the field of genetic and metabolic engineering and applying those developments to commercial products. After working with the early developers of recombinant DNA technology, Dr. Valle has spent the past ten years engineering organisms for successful commercial applications. Valle served as Director of Metabolic Engineering and most recently as Staff Scientist at Genencor, a top-ten global leader in biotech and one of the largest developers and manufacturers of industrial enzymes. Valle originally joined Genencor in 1997 as a visiting Professor in the Gene Expression Group from the National University of Mexico. He holds nearly a dozen combined patents and patent applications, and much of his lab work has resulted in successful product applications. At Genencor, he was heavily involved in the development of the fermentation organism for the production of 1,3-propanediol (PDO), reaching near theoretical yields through extensive engineering of the organism's metabolic pathways. Given the organism's ability to support required economic targets, DuPont and Tate & Lyle invested $100 million in a production facility in Loudon, Tennessee and commercial production of Bio-PDO began earlier this month.

"The challenge being addressed by LS9 is perhaps the most important our society will face for some time. I believe the LS9 technology and team are uniquely positioned to have a rapid and profound impact on this area, and I am very excited to contribute to their efforts," said Dr. Valle.

"We are very fortunate to have Fernando on board. Few people appreciate as deeply as Fernando the challenges of engineering an organism to commercially produce a commodity product by fermentation," said Stephen del Cardayre, Vice President of Research and Development for LS9. "While LS9 will face challenges, we are confident Fernando will accelerate our product development by anticipating hurdles and applying hard earned insight."

"There are not many people on the planet with Fernando's level of experience," added Doug Cameron, former head of biotechnology research at Cargill and acting Chief Executive Officer of LS9. "His track record speaks for itself."

About LS9

LS9, Inc., the Renewable Petroleum Company (TM), is a privately-held biotechnology company. LS9 is pursuing industrial applications of synthetic biology to produce biofuels that are compatible with existing fuel distribution and consumer infrastructure. LS9's DesignerBiofuels (TM) products are custom engineered in the lab to address immediate market needs for clean energy alternatives to petroleum. The company was founded in 2005 by leading scientists along with venture capital firms Flagship Ventures and Khosla Ventures. LS9 is headquartered in San Carlos, California, in the heart of Silicon Valley. http://www.ls9.com/.

CONTACT

Tim Gnatek, tim@bluepractice.com
or
Jessica Switzer, jessica@bluepractice.com

both of Blue Practice, +1-415-381-1100, both for LS9, Inc.